Bio-Rad Laboratories, Inc.

Equities

BIO

US0905722072

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 04:00:02 2024-04-18 pm EDT 5-day change 1st Jan Change
281 USD -3.38% Intraday chart for Bio-Rad Laboratories, Inc. -9.89% -12.97%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Zacks Investment Research Lowers Price Target on Bio-Rad Laboratories to $285 From $322 MT
Oncocyte Corporation and Bio-Rad Laboratories, Inc. Partner on Global Launch of Transplant Assay CI
Bio-Rad Laboratories COO Andrew Last to Retire in September MT
Bio-Rad Laboratories, Inc. Announces Chief Operating Officer Andrew Last to Retire CI
RBC Trims Price Target on Bio-Rad Laboratories to $474 From $480, Keeps Outperform Rating MT
North American Morning Briefing : Focus Turns to -2- DJ
Citigroup Downgrades Bio-Rad Laboratories to Neutral From Buy, Adjusts Price Target to $365 From $400 MT
Biodesix Strikes New Research Deal With Memorial Sloan Kettering Cancer Center MT
Bio-Rad Laboratories Appoints Roop Lakkaraju as CFO MT
Bio-Rad Laboratories, Inc. Appoints Roop K. Lakkaraju as Chief Financial Officer, Effective April 15, 2024 CI
Bio-Rad Laboratories, Inc. Appoints Roop K. Lakkaraju as New Executive Vice President Effective April 15, 2024 CI
Transcript : Bio-Rad Laboratories, Inc. Presents at Citi?s 2024 Unplugged Medtech and Life Sciences Access Day, Feb-29-2024 02:30 PM
Bio-rad Laboratories Insider Sold Shares Worth $1,008,000, According to a Recent SEC Filing MT
UBS Adjusts Bio-Rad Laboratories Price Target to $420 From $395, Maintains Buy Rating MT
RBC Trims Price Target on Bio-Rad Laboratories to $480 From $484, Keeps Outperform Rating MT
Bio Rad Labs rises after posting upbeat fourth-quarter profit RE
Bio-Rad Laboratories Q4 Adjusted Earnings, Revenue Decline, Shares Rise After-Hours MT
Transcript : Bio-Rad Laboratories, Inc., Q4 2023 Earnings Call, Feb 15, 2024
Earnings Flash (BIO.B) BIO-RAD LABORATORIES Posts Q4 Revenue $681.2M, vs. Street Est of $686.6M MT
Earnings Flash (BIO.B) BIO-RAD LABORATORIES Reports Q4 EPS $3.10, vs. Street Est of $2.87 MT
Bio-Rad Laboratories, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Bio-Rad Laboratories, Inc. Appoints Norman Schwartz as Principal Financial Officer CI
Bio-Rad Laboratories, Inc. Enters into Credit Agreement CI
Slow start for Wall Street Our Logo
Analyst recommendations: Blackstone, Citigroup, Icon, Amazon, Broadcom... Our Logo
Chart Bio-Rad Laboratories, Inc.
More charts
Bio-Rad Laboratories, Inc. is specialized in the development, manufacturing and marketing of products used in life sciences research, clinical diagnostics and analytical chemistry. Net sales break down by activity as follows: - manufacture of clinical diagnostic tests and automated test systems (51.8%). The group also offers test kits, quality control systems and related IT systems; - manufacture of reagents, equipment and instruments for biological research (48.1%): for the separation, identification and purification of chemical and biological substances (proteins, nucleic acids, bacteria, etc.) for the proteomics, genomics research, biopharmaceuticals, cell biology and food safety markets; - other (0.1%): in particular, manufacturing of analytical instruments. At the end of 2022, the Group has 16 production sites in the United States (5), Germany (3), France (2), China (2), Poland, the United Kingdom, Switzerland and Singapore. Net sales are distributed geographically as follows: the United States (41.2%), Europe (30.4%), Asia (22.8%) and other (5.6%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
281 USD
Average target price
428.9 USD
Spread / Average Target
+52.62%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. BIO Stock
  4. News Bio-Rad Laboratories, Inc.
  5. Bio Rad Laboratories : Zacks Investment Research Downgrades Bio-Rad Laboratories to Neutral From Outperform, Adjusts PT to $604 From $697